Tumor-associated antigen on nasopharyngeal carcinoma cell

Tumor-associated antigens on nasopharyngeal carcinoma cells comprise a group of molecular targets recognized by the immune system or therapeutic agents, frequently related to latent EBV infection (EBNA1, LMP1, and LMP2), immune checkpoints (such as PD-L1), or host molecules like HLA. These antigens play key roles in immune modulation, tumor immune escape, and cancer cell survival, making them critical for targeted immunotherapeutic strategies. Clinical efficacy of PD-1/PD-L1 blockade in recurrent and metastatic NPC highlights the importance of these targets, which are also being pursued for vaccine and cell therapy development.

Other names

EBV-associated antigens in NPCNPC tumor antigensNasopharyngeal carcinoma-associated antigensEBNA1LMP1LMP2

Immune checkpoint blockade (PD-1/PD-L1 inhibitors restore anti-tumor T cell activity); Cytotoxic T cell recognition (EBV antigens presented on HLA class I activate CD8+ T cells); Vaccine/Adoptive cell transfer (directed against viral or tumor antigens)